## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 1.51 fails VALUE criteria (<1.0); RSI 70 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (70).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It**
- Source: www.sharewise.com | 20251201T140003 | Somewhat-Bullish | Relevance: 99%
- This article analyzes Hologic, Inc. (HOLX) as a trending stock, focusing on key factors such as earnings estimate revisions, revenue growth forecasts, and valuation. It highlights Hologic's recent stock performance, Zacks Rank #3 (Hold) rating, and projections for future earnings and revenue. The analysis suggests that while the stock is trending due to search interest, its near-term performance is expected to be in line with the broader market.

**2. New research highlights Hologic’s AI tools for mammography**
- Source: DOTmed | 20251201T190447 | Somewhat-Bullish | Relevance: 99%
- New clinical data presented at RSNA 2025 highlights Hologic’s AI-based mammography technologies, including 3DQuorum and Genius AI Detection solutions. A retrospective study on 3DQuorum found it maintained cancer detection rates while improving workflow efficiency. Another study on Genius AI Detection showed higher cancer detection but reduced specificity, indicating an ongoing evaluation.

**3. Breast Health Performance Likely to Aid Hologic's Q1 Earnings**
- Source: MSN | 20251202T063751 | Somewhat-Bullish | Relevance: 99%
- Hologic's strong Breast Health segment performance is expected to be a key driver for its fiscal first-quarter 2024 earnings. Despite potential challenges in the Diagnostics and Medical Aesthetics divisions, growth in Breast Health, particularly from the Panther platform, is anticipated to support overall revenue. The company is set to release its Q1 2024 results on January 31, 2024.

**4. Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It**
- Source: www.sharewise.com | 20251202T033821 | Somewhat-Bullish | Relevance: 99%
- The article discusses Hologic, Inc. (HOLX) as a trending stock, highlighting its recent performance, earnings estimate revisions, revenue growth forecasts, and valuation metrics. It emphasizes Zacks' methodology of using earnings expectations to predict stock performance and provides an overview of HOLX's financial health and future prospects. The company currently holds a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market in the near term.

**5. RSNA 2025: Hologic Shares New Evidence on AI-Powered Mammography Solutions**
- Source: Medical Product Outsourcing | 20251201T161841 | Bullish | Relevance: 98%
- Hologic presented new data at RSNA 2025 showcasing the potential of its AI-powered mammography solutions, including 3DQuorum imaging technology and Genius AI Detection. Studies demonstrated that 3DQuorum can streamline radiologists' workflows without compromising cancer detection rates, while Genius AI Detection performed similarly to radiologists in identifying cancers. Hologic emphasizes its commitment to advancing breast health technologies and using AI to enhance efficiency and effectiveness in cancer screening.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $76 | $69 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Overbought RSI (70) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.51 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $77.32 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.51 |
| Forward P/E | 15.0 |
| Current P/E | 16.5 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.7% (minimal 5-day change). Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 70, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.73% (CS: 35) | Neutral |
| RSI_14 | 70.3 | Overbought |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.151x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $75.01
- **Stop Loss:** $74.11 (1.2% risk)
- **Target:** $75.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1055
- **Position Value:** $79,135.55
- **Portfolio %:** 79.14%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*